{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:48:47Z","timestamp":1765039727704,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mucosal melanoma, an aggressive type of malignancy different from the cutaneous melanomas commonly seen in the head and neck region, represents\u2009&lt;\u20091% of all malignant melanomas. The pathogenesis of mucosal melanoma is unknown. Targetable mutations commonly seen in cutaneous melanoma, such as in the <jats:italic>BRAF<\/jats:italic> and <jats:italic>NRAS<\/jats:italic> genes, have a lower incidence in mucosal melanoma. Mucosal melanoma carries a distinct mutational pattern from cutaneous melanoma. Surgery with negative margins is the first-line treatment for mucosal melanoma, and systemic therapy is not well defined. Talimogene laherparepvec, an oncolytic viral immunotherapy, is United States Food and Drug Administration approved for the treatment of advanced malignant cutaneous melanoma, with local therapeutic benefits. Mucosal melanoma was initially excluded from talimogene laherparepvec\u2019s initial phase\u00a0III clinical trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present the case of a white female patient in her 40s with past medical history of systemic lupus erythematous, scleroderma, and estrogen-receptor-positive invasive ductal breast carcinoma. Following a bilateral mastectomy, the patient was found to have <jats:italic>BRAF<\/jats:italic>-negative mucosal melanoma of her hard palate with a soft palate skip lesion. Owing to the presence of a skip mucosal lesion as well as the anticipated defect and need for free-flap reconstructive surgery, nonsurgical management was considered. The patient was referred to medical oncology, where\u2014based on the patient\u2019s complicated medical history and the risk of immunotherapy possibly worsening her prior autoimmune diseases\u2014local talimogene laherparepvec injections were chosen as the primary therapy for her mucosal lesions. Though talimogene laherparepvec is approved for the treatment of cutaneous melanoma, there are limited data available on the use of talimogene laherparepvec in mucosal melanomas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The patient had a complete local tumor response at both the primary lesion as well as the skip lesion with the local injections. She had no side effects and maintained a high quality of life during treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04554-8","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:02:07Z","timestamp":1716422527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-8127","authenticated-orcid":false,"given":"Saurabh D.","family":"Chitnis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolan B.","family":"Seim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"issue":"4","key":"4554_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cps.2021.05.010","volume":"48","author":"D Olla","year":"2021","unstructured":"Olla D, Neumeister MW. Mucosal melanoma. Clin Plast Surg. 2021;48(4):707\u201311.","journal-title":"Clin Plast Surg"},{"issue":"3","key":"4554_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-018-0675-0","volume":"20","author":"SS Yde","year":"2018","unstructured":"Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal melanoma: a literature review. Curr Oncol Rep. 2018;20(3):28.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"4554_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/cco-23-16","volume":"12","author":"YJ Jeong","year":"2023","unstructured":"Jeong YJ, Thompson JF, Ch\u2019ng S. Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review. Chin Clin Oncol. 2023;12(3):28.","journal-title":"Chin Clin Oncol"},{"key":"4554_CR4","doi-asserted-by":"publisher","first-page":"175883592211340","DOI":"10.1177\/17588359221134087","volume":"14","author":"I Kobeissi","year":"2022","unstructured":"Kobeissi I, Tarhini AA. Systemic adjuvant therapy for high-risk cutaneous melanoma. Ther Adv Med Oncol. 2022;14:17588359221134088.","journal-title":"Ther Adv Med Oncol"},{"key":"4554_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","volume":"61","author":"KW Nassar","year":"2020","unstructured":"Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol. 2020;61:139\u201348.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"4554_CR6","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373\u20139.","journal-title":"Cancer Sci"},{"issue":"6","key":"4554_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/cancers13061383","volume":"13","author":"PF Ferrucci","year":"2021","unstructured":"Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383.","journal-title":"Cancers"},{"issue":"1","key":"4554_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","volume":"18","author":"PK Bommareddy","year":"2017","unstructured":"Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma. Am J Clin Dermatol. 2017;18(1):1\u201315.","journal-title":"Am J Clin Dermatol"},{"key":"4554_CR9","doi-asserted-by":"crossref","unstructured":"Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664\u201378.","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G"},{"issue":"12","key":"4554_CR10","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/hed.24522","volume":"38","author":"RHI Andtbacka","year":"2016","unstructured":"Andtbacka RHI, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, et al. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB\/IIIC\/IV melanoma. Head Neck. 2016;38(12):1752\u20138.","journal-title":"Head Neck"},{"key":"4554_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fonc.2020.00611","volume":"10","author":"A Fr\u00f6hlich","year":"2020","unstructured":"Fr\u00f6hlich A, Hoffmann F, Niebel D, Egger E, Kukuk GM, Toma M, et al. Talimogene laherparepvec in advanced mucosal melanoma of the urethra upon primary resistance on immune checkpoint inhibition: a case report. Front Oncol. 2020;10:611.","journal-title":"Front Oncol"},{"issue":"3","key":"4554_CR12","first-page":"321","volume":"17","author":"C Drescher","year":"2019","unstructured":"Drescher C, Drexler K, Hilber H, Schmidt B, Haferkamp S. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2019;17(3):321\u20133.","journal-title":"J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG"},{"issue":"1","key":"4554_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1186\/s12885-022-09896-4","volume":"22","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Stahlie EHA, Franke V, Zijlker LP, Wilgenhof S, van der Noort V, et al. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. BMC Cancer. 2022;22(1):851.","journal-title":"BMC Cancer"},{"issue":"10","key":"4554_CR14","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","volume":"27","author":"R Dummer","year":"2021","unstructured":"Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB\u2013IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021;27(10):1789\u201396.","journal-title":"Nat Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04554-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04554-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:02:26Z","timestamp":1716422546000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04554-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4554"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04554-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,5,23]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflicts of interest need to be reported for all the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}